Literature DB >> 33073685

Multi-stage adaptive enrichment trial design with subgroup estimation.

Neha Joshi1, Crystal Nguyen1, Anastasia Ivanova1.   

Abstract

We consider the problem of estimating the best subgroup and testing for treatment effect in a clinical trial. We define the best subgroup as the subgroup that maximizes a utility function that reflects the trade-off between the subgroup size and the treatment effect. For moderate effect sizes and sample sizes, simpler methods for subgroup estimation worked better than more complex tree-based regression approaches. We propose a three-stage design with a weighted inverse normal combination test to test the hypothesis of no treatment effect across the three stages.

Entities:  

Keywords:  Adaptive enrichment; predictive biomarker; subgroup estimation

Mesh:

Year:  2020        PMID: 33073685      PMCID: PMC7954857          DOI: 10.1080/10543406.2020.1832109

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  19 in total

1.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.

Authors:  Martin Jenkins; Andrew Stone; Christopher Jennison
Journal:  Pharm Stat       Date:  2010-12-08       Impact factor: 1.894

2.  Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Authors:  Boris Freidlin; Richard Simon
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

3.  Adaptive enrichment designs for clinical trials.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2013-03-21       Impact factor: 5.899

4.  Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.

Authors:  Ilya Lipkovich; Alex Dmitrienko; Ralph B
Journal:  Stat Med       Date:  2016-08-03       Impact factor: 2.373

5.  Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.

Authors:  Zhiwei Zhang; Ruizhe Chen; Guoxing Soon; Hui Zhang
Journal:  Stat Med       Date:  2017-09-26       Impact factor: 2.373

6.  Biomarker threshold adaptive designs for survival endpoints.

Authors:  Guoqing Diao; Jun Dong; Donglin Zeng; Chunlei Ke; Alan Rong; Joseph G Ibrahim
Journal:  J Biopharm Stat       Date:  2018-02-13       Impact factor: 1.051

7.  Inference for multimarker adaptive enrichment trials.

Authors:  Richard Simon; Noah Simon
Journal:  Stat Med       Date:  2017-08-10       Impact factor: 2.373

8.  A regression tree approach to identifying subgroups with differential treatment effects.

Authors:  Wei-Yin Loh; Xu He; Michael Man
Journal:  Stat Med       Date:  2015-02-05       Impact factor: 2.373

9.  The cross-validated adaptive signature design.

Authors:  Boris Freidlin; Wenyu Jiang; Richard Simon
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

10.  Overlapping Group Logistic Regression with Applications to Genetic Pathway Selection.

Authors:  Yaohui Zeng; Patrick Breheny
Journal:  Cancer Inform       Date:  2016-09-15
View more
  2 in total

Review 1.  Challenges and opportunities in biomarker-driven trials: adaptive randomization.

Authors:  Yeonhee Park
Journal:  Ann Transl Med       Date:  2022-09

2.  The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.

Authors:  Anastasia Ivanova; Elliot Israel; Lisa M LaVange; Michael C Peters; Loren C Denlinger; Wendy C Moore; Leonard B Bacharier; M Alison Marquis; Nathan M Gotman; Michael R Kosorok; Chalmer Tomlinson; David T Mauger; Steve N Georas; Rosalind J Wright; Patricia Noel; Gary L Rosner; Praveen Akuthota; Dean Billheimer; Eugene R Bleecker; Juan Carlos Cardet; Mario Castro; Emily A DiMango; Serpil C Erzurum; John V Fahy; Merritt L Fajt; Benjamin M Gaston; Fernando Holguin; Sonia Jain; Nicholas J Kenyon; Jerry A Krishnan; Monica Kraft; Rajesh Kumar; Mark C Liu; Ngoc P Ly; James N Moy; Wanda Phipatanakul; Kristie Ross; Lewis J Smith; Stanley J Szefler; W Gerald Teague; Michael E Wechsler; Sally E Wenzel; Steven R White
Journal:  J Biopharm Stat       Date:  2020-09-17       Impact factor: 1.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.